Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Mediwound Ltd

Healthcare US MDWD

14.21USD
0.03(0.21%)

Last update at 2026-06-08T20:01:00Z

Day Range

14.0114.64
LowHigh

52 Week Range

7.1019.86
LowHigh

Fundamentals

  • Previous Close 14.18
  • Market Cap155.57M
  • Volume175187
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.76300M
  • Revenue TTM18.69M
  • Revenue Per Share TTM2.07
  • Gross Profit TTM 13.16M
  • Diluted EPS TTM-0.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -19.52100M -13.52400M -9.27600M 2.07M -5.66500M
Minority interest - - - - -
Net income -19.59900M -13.55100M -9.60100M 3.72M -1.05700M
Selling general administrative 8.33M 6.11M 8.69M 9.31M 7.99M
Selling and marketing expenses 2.04M 3.39M 3.23M 4.06M 4.19M
Gross profit 13.16M 8.77M 7.54M 19.94M 1.31M
Reconciled depreciation 1.27M 1.24M 1.09M 1.15M 0.58M
Ebit -8.34500M -11.22100M -8.84000M 4.49M -3.96000M
Ebitda -9.33100M -9.98300M -7.75000M 5.64M -3.38300M
Depreciation and amortization -0.98600M 1.24M 1.09M 1.15M 0.58M
Non operating income net other - - - - -
Operating income -8.34500M -11.22100M -8.84000M 4.49M -3.96000M
Other operating expenses 34.84M 34.98M 30.60M 27.30M 7.36M
Interest expense 8.92M 0.90M 0.83M 0.93M 0.89M
Tax provision 0.08M 0.03M - - -
Interest income 0.27M 0.01M 0.30M 0.43M 0.41M
Net interest income -2.25800M -1.08200M -0.54900M -2.54900M -1.48600M
Extraordinary items - - - 2.89M 4.61M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.08M 0.03M 0.33M -1.65200M -9.68900M
Total revenue 26.50M 23.76M 21.76M 31.79M 3.40M
Total operating expenses 21.51M 19.99M 16.39M 15.45M 5.27M
Cost of revenue 13.33M 14.99M 14.22M 11.85M 2.09M
Total other income expense net -11.17600M -2.30300M -0.43600M -2.42700M 6.57M
Discontinued operations - - 0.08M 2.89M 4.61M
Net income from continuing ops -19.59900M -13.55100M -9.27600M 2.07M -5.66500M
Net income applicable to common shares -19.59900M -13.55100M -9.19600M 4.96M -1.05700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 66.46M 50.02M 19.74M 31.07M 40.59M
Intangible assets 0.17M 0.23M 0.30M 0.36M 0.43M
Earning assets - - - - -
Other current assets 0.72M 9.98M 2.71M 0.57M 0.40M
Total liab 27.19M 39.10M 24.33M 23.80M 25.42M
Total stockholder equity 31.59M 10.91M -4.58200M 7.27M 15.17M
Deferred long term liab - - - - -
Other current liab 4.92M 6.34M 2.41M 1.75M 0.57M
Common stock 0.18M 0.14M 0.07M 0.07M 0.07M
Capital stock 0.18M 0.14M 0.07M 0.07M 0.07M
Retained earnings -174.82200M -168.10600M -148.50700M -134.95600M -125.76000M
Other liab - 26.20M 12.21M 13.79M 13.04M
Good will - - - - -
Other assets - 0.36M 0.47M - 0.00600M
Cash 12.03M 33.90M 11.05M 17.38M 7.24M
Cash and equivalents - - - - -
Total current liabilities 10.83M 12.06M 10.72M 8.27M 10.37M
Current deferred revenue 0.02M 0.06M 0.54M 0.46M 0.25M
Net debt -5.32200M -33.04900M -9.65500M -15.63500M -5.23600M
Short term debt 0.36M - 3.08M 3.06M 5.49M
Short long term debt - - - - -
Short long term debt total 6.71M 0.85M 1.39M 1.74M 2.01M
Other stockholder equity 206.25M 178.88M 143.87M 142.19M 140.87M
Property plant equipment - 3.58M 4.03M 4.51M 4.53M
Total current assets 49.70M 45.84M 14.95M 26.19M 35.62M
Long term investments - - - - -
Net tangible assets - 10.68M -4.87900M 6.91M 14.74M
Short term investments 29.68M - 0.00000M 4.02M 22.04M
Net receivables 4.42M 9.53M 2.71M 3.23M 4.55M
Long term debt - - - - -
Inventory 2.85M 1.96M 1.20M 1.38M 1.61M
Accounts payable 5.53M 5.66M 4.69M 2.99M 4.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01800M -0.00500M -0.01900M -0.04000M -0.01700M
Additional paid in capital - - - - -
Common stock total equity - - - 0.07M 0.07M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.18M 0.36M 0.47M - 0.00600M
Deferred long term asset charges - - - - -
Non current assets total 16.76M 4.18M 4.79M 4.88M 4.97M
Capital lease obligations 6.35M 0.85M 1.39M 1.74M 2.01M
Long term debt total - - - - 2.01M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.48100M 4.00M 18.03M -6.89700M -17.04000M
Change to liabilities 0.41M 1.72M -1.09600M 1.35M -0.53600M
Total cashflows from investing activities -0.48100M 3.55M 17.39M -6.89700M -17.04000M
Net borrowings -0.70100M -0.69300M -0.50800M -0.63000M -0.63000M
Total cash from financing activities 35.76M -1.05000M -0.62900M -1.00600M 0.05M
Change to operating activities 0.65M -2.74700M -0.49200M 6.62M -0.46700M
Net income -19.59900M -13.55100M -9.19600M 4.96M -1.05700M
Change in cash 22.85M -6.33000M 10.13M 0.53M -29.35300M
Begin period cash flow 11.05M 17.38M 7.24M 6.72M 36.07M
End period cash flow 33.90M 11.05M 17.38M 7.24M 6.72M
Total cash from operating activities -11.88500M -8.91600M -6.89500M 8.29M -12.15400M
Issuance of capital stock 38.38M - - - -
Depreciation 1.27M 1.24M 1.09M 1.15M 0.58M
Other cashflows from investing activities 0.07M 0.04M 0.27M -1.05500M 0.11M
Dividends paid - - - - -
Change to inventory -0.72100M 0.26M 0.14M 0.07M 0.21M
Change to account receivables -7.58200M 0.93M 1.39M -3.55300M -0.21100M
Sale purchase of stock - - - - -
Other cashflows from financing activities -1.91500M -1.05000M -0.12100M -1.00600M 0.05M
Change to netincome 13.69M 3.23M 1.27M -2.30700M -10.66600M
Capital expenditures 0.56M 0.49M 0.92M 0.79M 0.53M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -7.24400M 0.16M -0.06100M 4.49M -1.00800M
Stock based compensation 1.95M 1.67M 1.32M 1.23M 0.65M
Other non cash items 11.74M 1.69M 0.32M -1.68500M -11.51200M
Free cash flow -12.44000M -9.40500M -7.81800M 7.50M -12.68800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MDWD
Mediwound Ltd		 0.03 0.21% 14.21 - - 8.12 4.80 6.24 -24.2828
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Mediwound Ltd

42 Hayarkon Street, Yavne, Israel, 8122745

Key Executives

Name Title Year Born
Prof. Lior Rosenberg M.D. Co-Founder & Medical Director 1946
Mr. Boaz Gur-Lavie CPA, M.B.A. Chief Financial Officer 1974
Mr. Yaron Meyer Adv. Exec. VP, Gen. Counsel & Corp. Sec. 1979
Dr. Ety Klinger Chief R&D Officer 1962
Mr. Ofer Gonen B.Sc. Chief Exec. Officer 1973
Mr. Tzvi Palash B.Sc., M.Sc. Chief Operating Officer 1957
Mr. Stephen T. Wills CPA, CPA, MST Exec. Director 1957
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. Chief Medical Officer NA
Ms. Hani Luxenburg Chief Financial Officer 1973
Mr. Ofer Gonen B.Sc. Chief Executive Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.